Anita Milicic studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing MSc in Genetics and DPhil in Immunology at the University of Oxford. In 2009 she joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility, procuring and testing a range of novel vaccine adjuvants for human and veterinary application.

Anita now leads the Vaccine Formulation and Adjuvants Group, exploring immune mechanisms of vaccines and adjuvants and developing novel vaccine formulations and delivery modalities. Her research interest is in understanding the processes that underpin the immune response to vaccination, in particular the interplay between innate and adaptive immunity. Anita Milicic leads the Vaccine Formulation and Adjuvants Group at the Jenner Institute, Oxford, exploring immune mechanisms of vaccines and adjuvants and developing novel vaccine formulations and delivery modalities. Her research interest is in understanding the processes that underpin the immune response to vaccination, in particular the interplay between innate and adaptive immunity. This is studied through modulating the context (i.e. vaccine platform) and kinetics (bolus, continuous) of vaccine antigen delivery, employing a combination of in vitro and in vivo animal model systems and human in vitro and ex vivo studies.

Apart from research, Anita is involved in teaching at Oxford and externally and writing popular science articles on vaccination and vaccine adjuvants. Anita is the Jenner Institute Director of Graduate Studies and the Lead for Public Engagement with Research.